Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.45 |
| ▸ | JAK3 | P52333 | 5/20 | 0.41 |
| ▸ | BTK | Q06187 | 4/20 | 0.41 |
| ▸ | BLK | P51451 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21590835 | 0.77 | GPR119 (0.51) | — | |
| SCHEMBL26217925 | 0.74 | ACHE (0.46) | EGFRERBB2JAK3BTKBLK | |
| SCHEMBL22196870 | 0.74 | BTK (0.52) | EGFRERBB2JAK3BTKBLK | |
| SCHEMBL1507208 | 0.72 | HRH3 (0.48) | — | |
| SCHEMBL22174233 | 0.71 | TET3 (0.51) | EGFRERBB2BTK | |
| SCHEMBL20069144 | 0.71 | PDE9A (0.44) | — | |
| SCHEMBL20147951 | 0.71 | PDE9A (0.35) | — | |
| SCHEMBL22663347 | 0.70 | RET (0.38) | — | |
| SCHEMBL22174244 | 0.69 | EGFR (0.54) | EGFRERBB2 | |
| SCHEMBL20412702 | 0.69 | HRH3 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771689-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771689-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| US-20210002337-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | THE SCRIPPS RESEARCH INSTITUTE | 2021-01-07 | — | — | US | disclosed |
| US-10869860-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-10781239-B2 | In vivo engineered cereblon protein | VIVIDION THERAPEUTICS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200216507-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2020-07-09 | — | — | US | disclosed |
| US-20200206201-A1 | CEREBLON MODULATORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | EGFR 4245/4885ERBB2 4374/4885JAK3 3827/4885 |
| US-20200216507-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | EGFR 4245/4885ERBB2 4374/4885JAK3 3827/4885 |
| US-11771689-B2 | Cereblon modulators and uses thereof | CRBN, CBFB, CNN2 | EGFR 1232/4885ERBB2 3488/4885JAK3 3991/4885 |
| US-10869860-B2 | Cereblon modulators and uses thereof | CRBN, CBFB, CNN2 | EGFR 1232/4885ERBB2 3488/4885JAK3 3991/4885 |
| US-20210002337-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | EGFR 4245/4885ERBB2 4374/4885JAK3 3827/4885 |
| US-20200206201-A1 | CEREBLON MODULATORS AND USES THEREOF | CRBN, CBFB, CNN2 | EGFR 1232/4885ERBB2 3488/4885JAK3 3991/4885 |
| US-10781239-B2 | In vivo engineered cereblon protein | CRBN, CDR2, DCUN1D4 | EGFR 4245/4885ERBB2 4374/4885JAK3 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.